Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vasopressin acts in the subfornical organ to decrease blood pressure

P M Smith1, A V Ferguson

  • 1Department of Physiology, Queens University, Kingston, Ont., Canada.

Neuroendocrinology
|August 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Skeletal muscle mitochondrial dysfunction is associated with increased Gdf15 expression and circulating GDF15 levels in aged mice.

Scientific reports·2025
Same author

The effect of age and sex on peak oxygen uptake during upper and lower body exercise: A systematic review.

Experimental gerontology·2024
Same author

Exploring the genetics underpinning dynamic laryngeal collapse associated with poll flexion in Norwegian-Swedish Coldblooded Trotter racehorses.

Equine veterinary journal·2019
Same author

The transcriptome of the rat subfornical organ is altered in response to early postnatal overnutrition.

IBRO reports·2018
Same author

The subfornical organ: A novel site for prolactin action.

Journal of neuroendocrinology·2018
Same author

A method for securing the temporary lead(s) in sacral nerve stimulation.

Annals of the Royal College of Surgeons of England·2017
Same journal

Passive Smoking and Thyroid Diseases: Association by Mendelian Randomization Study.

Neuroendocrinology·2026
Same journal

Erratum.

Neuroendocrinology·2026
Same journal

Stress as a Neuroendocrine Modulator of the Reproductive Axis: Roles of Glucocorticoids, Kisspeptin and Serotonergic Signalling in Animal Models.

Neuroendocrinology·2026
Same journal

Pathological Classification and Clinical Characteristics of Growth Hormone-Secreting PitNETs.

Neuroendocrinology·2026
Same journal

Proximal-to-distal gradient and its implications in differentiation and prognosis in colorectal neuroendocrine neoplasms: the RGETNE-HERACLES study.

Neuroendocrinology·2026
Same journal

Inflammatory Signaling and Emotional Symptoms in Hashimoto's Thyroiditis Beyond Thyroid Function Status.

Neuroendocrinology·2026
See all related articles

Vasopressin (VP) acting on the subfornical organ (SFO) lowers blood pressure in rats. This effect is specific to the SFO and blocked by V1 receptor antagonists, highlighting the SFO's role in cardiovascular control.

Area of Science:

  • Neuroscience
  • Cardiovascular Physiology
  • Endocrinology

Background:

  • Vasopressin (VP) is a vasoactive peptide involved in central cardiovascular regulation.
  • The subfornical organ (SFO), a circumventricular organ (CVO), possesses VP receptors and connections to autonomic control centers.
  • The SFO's role in VP-mediated cardiovascular feedback remains to be fully elucidated.

Purpose of the Study:

  • To investigate the physiological effects of activating VP receptors within the SFO.
  • To determine if VP microinjections into the SFO influence blood pressure and heart rate.
  • To ascertain the specificity of VP's action within the SFO for cardiovascular control.

Main Methods:

  • Microinjection of vasopressin (VP) into the SFO of urethane-anesthetized rats.

Related Experiment Videos

  • Measurement of blood pressure (BP) and heart rate (HR) following microinjections.
  • Comparison of VP effects in the SFO versus non-SFO tissue and the third ventricle.
  • Assessment of VP's action using a V1 receptor antagonist.

    • Main Results:

    • Microinjection of VP into the SFO caused significant decreases in blood pressure without altering heart rate.
    • VP microinjections into non-SFO tissue did not affect blood pressure or heart rate.
    • VP microinjection into the third ventricle increased blood pressure, with no change in heart rate.
    • Systemic administration of a V1 receptor antagonist abolished the hypotensive effects of VP in the SFO.

    Conclusions:

    • The subfornical organ (SFO) is a critical site for vasopressin (VP)-mediated cardiovascular regulation.
    • Activation of VP receptors in the SFO leads to a decrease in blood pressure.
    • These findings suggest the SFO plays a key role in the feedback loop controlling autonomic pathways for cardiovascular homeostasis.